A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -

Exclusion Criteria

• •Endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's syndrome, etc.
• •Heart disease (heart failure, angina pectoris, myocardial infarction)
• •Cholelithiasis
• •Severe renal disability (SCr \> 2.0 mg/dL)
• •Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], alkaline phosphatase)
• •History of narrow angle glaucoma
• •History of stroke or temporary ischemic cardioplegia
• •History of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
• •Use of medication that can affect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medications can affect on absorption, metabolism, excretion)
• •Use of CNS stimulant medication for weight loss
• •Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
• •history of weight loss surgery, such as bariatric surgery, etc.
• •Subjects who are judged to be inappropriate for the clinical study by the researchers
• •Women who were pregnant, lactating or have the chances of pregnancy who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.)
• •Use of other investigational product within last 1 month
• •10 percent reduction in body weight over 6 months
• •Decided to quit smoking over the last 3 months or have irregular smoking habits